[Studies on the new long-acting anti-cancer preparation, 5-fluorouracil-polyglycolic acid composite].
Polymer polyglycolic acid is biocompatible in the body. A needle-shaped long-acting anti-cancer preparation (F-PGA needle) was prepared by compounding polyglycolic acid and the anti-cancer drug 5-Fluorouracil (5-FU). The release of 5-FU from the needle was maintained for about 10 days, and the needle disappeared after one year. A clinical study with the F-PGA needle was made on patients with terminal carcinomas. Shrinkage of tumors and tumor necrosis were observed in two patients with metastatic liver carcinomas. The F-PGA needle supplies high-dose 5-FU locally for a long time with fewer side effects by embedding it into the tumor tissue. Therefore the F-PGA needle can be said to be promising in the treatment of unresectable cancer as a topical application of chemotherapy.
D000368:Aged; D003692:Delayed-Action Preparations; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008875:Middle Aged; D009339:Needles; D011100:Polyglycolic Acid / Q000008:administration & dosage; D013274:Stomach Neoplasms / Q000473:pathology
D003692:Delayed-Action Preparations; D011100:Polyglycolic Acid; D005472:Fluorouracil